Institution identification

PURI

https://redirect.ema.europa.eu/resource/3331546

Institution ID

3331546

Institution full name and acronym

Shire

ENCePP partner

No
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Studies conducted by the institution

091301: FEIBA NF GLOBAL OUTCOME STUDY (FEIBA-GO) (091301: FEIBA-GO)
241501: Prospective and retrospective, non-interventional study to evaluate the safety and effectiveness of Obizur in real-life practice
ADVATE 2 mL (reconstituted in 2 mL SWFI) POST-AUTHORIZATION SAFETY SURVEILLANCE STUDY (ADVATE 2 mL PASS)
An Open-Label, Randosized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once-Daily and Twice-Daily Dose Regimens of recombinant human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously to Subjects with Hypoparathyroidism (SHP634-101)
Drug utilization study with VYVANSE® (lisdexamfetamine dimesilate) in Australia for Binge Eating Disorder
Non-Interventional Post-Authorization Safety Study on the Long-Term Safety of HyQvia in Subjects Treated with HyQvia (161302)
Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)
Pregnancy Registry to collect Long-Term Safety Data from Women treated with HyQvia
SHP503-803: Drug Utilization Study with Intuniv® in Australia
SHP617-404: A SWEDISH RETROSPECTIVE STUDY EVALUATING THE PATTERN OF PLENADREN USE FROM SWEDISH QUALITY REGISTRIES (SWE-DUS)
TAK-834-4008: Quantitative Testing of Patient and Healthcare Provider Knowledge, Attitudes, and Behavior About NATPARA® (Parathyroid Hormone) for Injection, for Subcutaneous Use (NATPARA KAB)
VPRIV® Non-Interventional Study in Patients Previously Treated with Other Enzyme Replacement Therapies (ERTs)/Substrate Reduction Therapies (SRTs) (SHP669-405)